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Introduction
This chapter describes the development and the current status of bioethics in
Switzerland with special emphasis on the historical evolution and the social and
cultural contexts that have shaped the debate in the country. Medical ethics
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developed in the late 1970s and was progressively institutionalized in the following
decades through the establishment of ethical committees, guidelines for health care
professionals, academic training in medical schools, and ethical consultation in
Swiss hospitals.
Over the past three decades, discussions within academia, policy making, and the
public arena have resulted in the adoption of regulations on several bioethical issues.
As elsewhere inWestern Europe, major issues of discussion include abortion and the
status of prenatal life, assisted suicide, end-of-life care, organ transplantation, repro-
ductive technologies, ethical issues of genetic technologies, and protection of human
subjects of research. Nevertheless, these issues have a considerable bearing on Swiss
public debate because of the system of semi-direct democracy, in which citizens can
be called upon to vote on legislative proposals or on challenges to parliamentary bills.
Decentralized governance, cultural and confessional differences, as well as the value
placed on individual choices have largely influenced discussions, laws, and practices
regarding many bioethical issues outlined in this chapter.
Bioethics Development
When and How Has Bioethics Started?
Certain aspects of ethical issues in medical care were part of graduate courses of
moral theology and forensic medicine before the existence of bioethics as a distinct
field. From the 1970s, medical ethics began to be considered as a specific field
grounded in philosophical ethics and dealing with normative questions in medical
practice and research.
In 1979, the Swiss Academy of Medical Sciences (SAMS) (http://www.samw.
ch/en/News/News.html), founded by medical schools and health care professions,
set up a SAMS Central Ethical Committee (http://www.samw.ch/en/Ethics/CEC.
html) in charge of establishing guidelines on controversial issues in medical
practice. Over time, some of these guidelines have acquired binding authority,
either through endorsement by the Swiss Medical Association (http://www.fmh.
ch/index.html) as part of the professional code of physicians or by being referred to
by laws or by case law. In the following decades, academia progressively took an
interest in ethics, in general and medical ethics in particular. Progressively, Swiss
universities established chairs in ethics within philosophy departments and medical
schools.
Who Have Been the Major Actors/Forces?
Switzerland is a multicultural federal republic with a system of semi-direct democ-
racy where governance is strongly decentralized. This is also reflected in bioethics.
The major actors in the field are as follows:
– The Swiss Academy of Medical Sciences (SAMS), based in Basel
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– The Zurich University Centre for Ethics (ZUCE) (http://www.ethik.uzh.ch/
index_en.html).
– The Institute for Biomedical Ethics (IEB) (http://www.unige.ch/medecine/ib/
accueil.html) at the University of Geneva.
– More recently, the University of Basel’s Institute for Biomedical
Ethics (IBMB) (http://ibmb.unibas.ch/) and the University of Lausanne’s
ETHOS – Interdisciplinary Ethics Platform (http://www.unil.ch/ethos/
page60109_en.html).
In December 1998, the Swiss National Advisory Commission on Biomedical
Ethics (NEK-CNE) (http://www.bag.admin.ch/nek-cne/04236/index.html?lang¼en)
was set up as an independent, extra-parliamentary deliberative body, with the
mission to promote public debate and advise policymakers on ethical issues in the
field of biomedical research and practice. The Federal Ethics Committee on
Non-Human Biotechnology (ECNH) (http://www.ekah.ch/en/index.html) was
established the same year as an independent expert committee to advise authorities
on ethical issues of nonhuman biotechnology and gene technology. Ethics commis-
sions providing advice for clinical practice are increasingly present in Swiss
hospitals.
The Confederation also established the Centre for Technology Assessment
TA-SWISS (http://www.ta-swiss.ch/en/) with a view to investigate the social
impact of new technologies and advise the Parliament and the Federal Council on
controversial technologies. Research in the field of biomedical ethics is mainly
sustained by the Swiss National Science Foundation (SNSF) (http://www.snf.ch/E/
Pages/default.aspx) through various forms of financial support to academic institu-
tions and individual researchers and through national programs on specific topics.
Among nonacademic institutions, the Brocher Foundation (http://www.brocher.ch/
pages/default.asp?lang¼en) supports research on ethical, social, and legal issues of
biomedical technologies.
The Swiss Society for Biomedical Ethics (SGBE/SSEB) (http://www.bioethica-
forum.ch/content/e_SGBESSEB.php) – a multidisciplinary, multilingual, and
non-confessional association of scholars and practitioners joining various ethical
perspectives and a pluralistic approach to bioethical issues – promotes research and
training in bioethics (see section “What Resources Have Been Developed (e.g.,
Books, Programs, Media, Networks, Societies)?” below).
What Have Been the Major Concerns Over Time?
During the 1990s, the Swiss debate was characterized by lively public discussions
on ethical dilemmas related to genetics, reproductive technologies, and end-of-life
care. Beside these major topics, the bioethical debate within academia,
policy making, and the public arena has focused on organ transplantation, the
protection of human subjects of research, experimentation on animals, abortion,
and the ethical status of human prenatal life, the prevention of infectious diseases,
and patient rights.
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What Resources Have Been Developed (e.g., Books, Programs,
Media, Networks, Societies)?
Numerous publications in the field are produced at the local level in the various
linguistic regions of the country. In addition, several resources in bioethics have been
developed at the national level. The SwissAcademy ofMedical Sciences (SAMS) and
the Swiss Medical Association promoted the publication of a textbook of biomedical
ethics discussions and regulations in the country (Bondolfi and M€uller, 1999).
Since the early 1990s, the universities of Zurich and Geneva initiated
formal bioethics courses for medical students. Until 2006, the Swiss Society for
Biomedical Ethics (SGBE/SSBE) has organized a summer school for health care
professionals and researchers who did not have the opportunity to have training in
bioethics during their education. Every 2 years since 2005 and annually since 2009, the
SGBE/SSBEorganizesworkshopswhere research projects are presented and discussed.
Two main book series on bioethical research in Switzerland are published in
German and French by Schwabe editions in Basel within the collection Ethik und
Recht and by Georg editions in Geneva within the reader’s collection Controverses
en e´thique. The SGBE/SSBE publishes the journal Bioethica Forum (http://www.
bioethica-forum.ch/e_index.php), as well as a collection of thematic essays in
French and German entitled Folia Bioethica.
What Have Been the Steps/Measures Taken?
Over the past three decades, Switzerland has adopted regulations on several bio-
ethical issues, such as reproductive technologies (http://www.admin.ch/ch/d/sr/
c810_11.html), genetically modified organisms (http://www.admin.ch/ch/d/sr/
c814_91.html), research on human embryonic stem cells derived from spare
embryos (http://www.admin.ch/ch/d/sr/810_31/index.html), human genetic testing
(http://www.admin.ch/ch/d/sr/810_12/index.html) including prenatal testing and
newborn screening, and organ transplantation (http://www.bag.admin.ch/transplan-
tation/00694/01739/index.html?lang¼de). A new law on biomedical research on
human subjects will soon become effective (http://www.bag.admin.ch/themen/
medizin/00701/00702/07558/index.html?lang¼de), and a far-reaching revision of the
civil code will make advance directives recognized on a federal level in 2013 (http://
www.ejpd.admin.ch/content/ejpd/de/home/themen/gesellschaft/ref_gesetzgebung/ref_
vormundschaft.html).
Whereas the cantons hold legal prerogative in the field of health care policy, on
most of the issues listed above, the Confederation enlarged the scope of its power,
otherwise limited to infectious disease control. Giving the Swiss Parliament the
authority to enact laws on additional topics requires a change in the Constitution,
which in turn requires that citizens be called upon to vote. In the last 30 years, this
happened regularly on many issues regarding medical practice and research.
It should be noted that abortion and assisted suicide are regulated by the Swiss
criminal code and that no specific legislation on these practices has been
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introduced. In particular, Articles 118–120 of the code authorize abortion on
demand in the first trimester and on medical indication thereafter, and Articles
115 and 114 legally condone assisted suicide for altruistic reasons and outlaw
“murder on demand by the victim” or voluntary active euthanasia.
The Swiss law on epidemics dates back to 1974 and has never been amended
over time. During the AIDS pandemic, no specific standards were introduced,
although information campaigns were strongly supported by public authorities to
prevent the spreading of the disease in the country.
Besides the regulatory activity of the Confederation, the Swiss Academy of
Medical Sciences (SAMS) regularly provides recommendations and guidance for
health care professionals on various topics relevant to medical practice and research
as outlined above.
Current Bioethics Infrastructure
Teaching of Bioethics at University and Other Levels
The teaching of bioethics is currently present in all the faculties of human and veterinary
medicine, in some faculties of sciences, and inmany bachelor- andmaster-level training
programs for health professionals. The Swiss Academy of Medical Sciences (SAMS) is
compiling a complete list of teaching institutions and programs. The federal law
defining training for the medical profession requires academic programs to include
courses on the ethical aspects of the professional activity, with a view to develop
students’ personal skills and social competences. Although education in bioethics is
compulsory for medical students, training programs can be defined by universities with
a high degree of autonomy.
Bioethics Committees
Research involving animals or human participants needs to obtain clearance from an
ethics committee, as is the case in all countries recognizing international ethical princi-
ples of biomedical research. A new federal law on biomedical research on human
subjects will come into force by 2014. Until then, the ethical review of research protocols
and the establishment of ethics committee fall under the jurisdiction of cantons. At
present, cantons where universities have faculties of medicine have set up cantonal ethics
committees, organized in various subcommittees covering different research fields.
Where no faculty of medicine exists, an inter-cantonal ethics committee is established,
with the exception of Ticino where the cantonal committee was created because of
intense research activities in the canton and because of its geographic isolation.
In addition to ethics committees for the review of research protocols, clinical
ethics committees are present in almost half of all Swiss hospitals to provide ethical
consultation to health care professionals (Hurst et al., 2008). The functioning of
each clinical ethics committee is regulated by its statute.
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Expert Bodies/Centers
At the national level, two ethics committees exist in Switzerland to promote public
debate and advise policymakers on ethical issues: the Federal Ethics Committee on
Non-Human Biotechnology (ECNH) examines ethical issues of biotechnological
interventions on plants and animals, whereas the Swiss National Advisory Com-
mission on Biomedical Ethics (NEK-CNE) considers ethical and health policy
issues in the field of biomedicine.
Relevant Legislation
The relevant Swiss legislation in the field of bioethics is detailed in section “What
Have Been the Steps/Measures Taken”.
Public Debate Activities
In Switzerland, public discussion of bioethical issues is largely determined by the
political agenda set by the Parliament. However, the system of semi-direct democ-
racy, in which parliamentary bills can be called into question, new laws can be
proposed, and constitutional amendments can be passed by popular vote, have
a considerable bearing on public debate activities in the country. Bioethical issues
that are currently under discussion in the public debate include the following:
• The use and reimbursement of reproductive technologies, especially preimplan-
tation diagnosis.
• Various issues in environmental ethics, especially the regulation and use of
genetically modified organisms.
• The relevance of further regulating the legal practice of suicide assistance,
and/or of legalizing voluntary euthanasia.
• The application of patient rights within the health care system.
• The costs of the Swiss health care system and the ethical and health policy issues
relating to access to health care.
• Ethical issues of direct-to-consumer genetic testing.
Major Bioethics Issues and Discussions
Beginning of Life
Within academic discourse, dilemmas surrounding the ethical standing of human
prenatal life and reproductive technologies are discussed largely in the same terms
in Switzerland as elsewhere in Western Europe, and controversies run along similar
lines. Nevertheless, these issues have been particularly visible in Swiss public life
on account of the system of semi-direct democracy, in which citizens are regularly
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called upon to vote on legislative proposals or on challenges to bills adopted by
Parliament. In the last two decades, this occurred a number of times for topics
relevant to this section. In 2002, Parliament adopted a far-reaching reform of
criminal law as regards abortion, basing the protection of embryos and fetuses on
a “gradualist” view of their moral status – the view according to which the
appropriate protections grow, as it were, along with it. This made Swiss criminal
law much more liberal than the (nominally) conservative status quo. Conservatives
and certain religious circles gathered the requisite number of signatures to put the
issue before the people, but their challenge to a liberal abortion law was resound-
ingly defeated (72.2 % votes were in favor of the new law; a competing proposal to
prohibit abortion in most situations was defeated by 81.7 % of votes).
The ethics and politics of reproductive technologies as well as related issues such as
research using human embryonic stem cells show a far more complex picture. Broadly
speaking, Swiss legislation on reproductive technologies rests on the paradigm of
application within a nuclear family, recognizes an individual’s right to know her
biological ascendency, and has strictly banned the production of embryos for any
purpose other than implantation. At the same time, however, research is highly valued,
and this extends to human embryonic stem cells. In the early 1990s, a fairly restrictive
constitutional amendment was adopted (Article 119 of the Constitution) with strong
popular support at the time. Among other restrictions, oocyte donation, embryo
donation, and preimplantation genetic diagnosis (PGD) were outlawed, as were the
production of more than three embryos in vitro per cycle of fertility treatment; keeping
frozen spare embryos for an ulterior treatment cycle was also forbidden. In the early
years of this century, a bill softening these prohibitions in order to make human
embryonic stem cell research possible was put to the popular ballot and accepted
(66.4 % “yes” votes). Among other elements, this new law establishes a requirement
for parental consent for the use of surplus embryos in human embryonic stem cell
research (Porz, B€urkli, Barazzetti, Scully and Rehmann-Sutter, 2008). The climate of
public opinion on these issues seems to have changed. The prohibition of PGD is
currently challenged, and a correspondingly revised legislation is being discussed.
End of Life
The Swiss debate on end-of-life care can be traced back to the 1960s. Discussions
were nourished by philosophers, theologians, and health care professionals,
confronting new dilemmas of end-of-life care raised by medical progress. There
are many publications on the topic in Switzerland, although this literature is
relatively fragmented due to its multilingual character. Early discussion on end-
of-life care centered on a medical decision to limit life support of a dying person.
Eventually, this decision was not enacted, but it brought about an energetic debate
on withdrawing medical care at the end of life. In the wake of this discussion, the
Swiss Academy of Medical Sciences (SAMS) drew ethical recommendations that
allow doctors to withhold futile treatments to dying patients. Issued in 1976, the
SAMS guidelines have been regularly reviewed as the debate on end-of-life care in
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the country continued to evolve (revisions were published in 1981, 1988, 1995, and
2004). The analysis of the successive versions of the document shows a growing
consensus on the moral wrongness of futile medical care.
Besides issues of end-of-life care, the practice of assisted suicide has been
extensively discussed in the country (Pfister and Biller-Andorno, 2010). Assisted
suicide is legally condoned by Article 115 of the Swiss criminal law if the motive is
altruistic, and it can be performed by nonphysicians (Hurst and Mauron, 2003). The
viewpoint of the SAMS on assisted suicide has changed over time. While the 1995
revision of the SAMS guidelines (Available at http://www.samw.ch/de/Ethik/
Richtlinien/Archiv.html) stated that assisted suicide is “not a part of medical
activity,” the last version of the document (Swiss Academy of Medical Sciences,
2004a) acknowledges that a conscientious decision by a doctor to assist suicide
should be respected. During the last few years, the political discussion has focused
on whether to regulate both assisted suicide and voluntary euthanasia by law. In
June 2011, the Parliament decided to maintain the status quo.
Discussions about palliative care and advanced directives were less controver-
sial and have rapidly reached a general consensus. Palliative care is promoted and
sustained by the Confederation and the cantons. Advanced directives, which
already exist in several cantons, are recognized on a federal level by a revision of
the Swiss civil code, as of 2013.
Health and Disease
In Switzerland, coverage by medical insurance is based on the presence of
disease and the indication for medical treatment, making the definition of
what constitutes disease, or not, a key element. Excluded areas include long-
term care, viewed as required by old age rather than disease, but also contra-
ception and fertility treatments, both of which are considered lifestyle choices
rather than health issues. More recently, coverage for vision correction in
childhood has been excluded from coverage: based on statistical frequency, it
was argued that it was normal and thus not a health condition.
Health Care System, Access to Health Care
The Swiss health care system is a universal coverage system based on an
individual mandate for the purchase of state-regulated but privately managed
health insurance, with subsidies toward this purchase for lower income groups
(Gagnebin and Sprumont, 2009). Voluntary additional insurance can be pur-
chased by individuals who so choose; it covers greater comfort and choice of
provider in hospitals, as well as certain interventions not covered by basic
health insurance such as travel insurance or some forms of alternative medicine.
Despite universal coverage and a very well-funded health system with dense
regional access, barriers to access exist. The most visible one is a high rate of
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out-of-pocket payments, which have been shown to lead some persons to forgo
needed care (Wolff, Gaspoz and Guessous, 2011). Moreover, as outlined above
(see section “Health and Disease”), coverage under basic insurance is predi-
cated on interventions targeting disease, making the definition of what consti-
tutes disease, or not, a key element. Dental care is also excluded from health
care coverage. Rather than being based on a link between dental care and
personal behavior in the prevention of dental disease, however, this exclusion
is based on early requests by dentists to be excluded from what they viewed as
obligations linked to their interventions’ inclusion under the basic health insur-
ance mandate.
Coverage for alternative medicine has been the object of a long-standing
debate in Switzerland, where some forms of alternative therapy have originated
and where several have been in use for a long time. Coverage of medical
interventions is legally predicated on the intervention being “effective, appro-
priate, and efficient.” Thus, one part of the discussion regarding alternative
medicine has centered on its effectiveness. Despite a negative recommendation
by the official commission on health coverage, however, the exclusion of these
forms of alternative medicine proved so unpopular that they were covered
despite not being proven effective.
Moreover, discussions regarding the possibility of excluding marginally benefi-
cial interventions have taken place (Zimmermann-Acklin, 2005). These have been
politically difficult and hence sporadic.
Traditional Medicine
As outlined above (see section “Health Care System, Access to Health Care”),
coverage for alternative medicine has been the object of a long-standing debate
in Switzerland, where some forms of alternative therapy have originated and
where several have been in use for a long time. Several forms of alternative
medicine – phytotherapy, homeopathy, Chinese traditional medicine, neural
therapy, and anthroposophic medicine – are practiced by physicians with offi-
cially recognized courses of training. Coverage of medical interventions, how-
ever, is legally predicated on the intervention being “effective, appropriate, and
efficient.” Thus, one part of the discussion regarding alternative medicine has
centered on its effectiveness. Despite a negative recommendation by the official
commission on health coverage, however, the exclusion of these forms of
alternative medicine proved so unpopular that they were covered despite not
being proven effective.
Another part of the discussion has centered on the place of alternative medicine
in medical training. Since 2009, Switzerland is required by its Constitution to “take
alternative medicines into account”. Although it is not entirely clear what this might
mean for medical schools, it is broadly accepted that making students critically
aware of alternative medicines and their claims will be the main application of this
law in universities.
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Genetics
Discussions about human genetics in Switzerland cover a wide range of topics, as it
is the case elsewhere: from presymptomatic and susceptibility testing to DNA
fingerprinting for criminal investigations; from disclosure and confidentiality of
test results to gene therapy. A Federal Act on Human Genetic Testing (http://www.
admin.ch/ch/e/rs/c810_12.html) was enacted in 2004 to regulate human genetic
testing in the country.
Ethical and science policy issues that have been extensively discussed in the
Swiss context have centered on the use of genetically modified (GM) crops in
agriculture and on the commercialization of GM food, ensuing from the lack of
specific regulations and transparent authorization procedures. For nearly 15 years,
from the first field experiments in the early 1990s to the moratorium for GM crops
that was passed in 2005, the debate spread out across the country in the form of
a controversy about safety and environmental risks. The controversy was triggered
by the action taken by ecologist groups who proposed an initiative for a restrictive
regulation of various aspects of GM food, including patenting and commercializa-
tion. In response, molecular biologists organized protest marches in defense of new
genetic technologies, also supported by pharmaceutical companies. Farmers
concerned about the coexistence of traditional and genetically modified crops
also called for a careful consideration of environmental and economic impacts of
GM crops onto the small-size Swiss agriculture. The spreading controversy forced
public authorities to accelerate the process of planning regulations. A directive on
the labelling of food containing GM organisms was enforced in 1996, and the
Federal Ethics Committee on Non-Human Biotechnology (ECNH) was set up in
1998 to examine ethical issues of developments in gene and biotechnology with
a view to assess their impacts on humans and the environment. The ECNH should
work in cooperation with the Swiss Expert Committee for Biosafety (SECB)
(http://www.efbs.admin.ch/en/index.html) to review experimental protocols of
GM crops field experiments and to inform the Federal Office for Environment
(FOEN) (http://www.bafu.admin.ch/index.html?lang¼en) in charge of giving
the final clearance. The initiative proposed by ecologists was eventually voted
in 1998 and rejected by a majority of the electorate (66 %). This result did not
close the controversy in the country, which turned to be focused on field exper-
iments. Notwithstanding the approval of the SECB and the favorable evaluation
from several scientists, between 1999 and 2001, the FOEN repeatedly denied
authorization of field experiments on the basis of the precautionary principle.
The decision of the FOEN was contested by scientists who considered field
experiments essential to their research work, which was conducted under
a national research strategy on biotechnology financed by the Swiss National
Science Foundation (SNSF). This crisis in national science policy was the
consequence of various ethical and social issues of GM food that were still
under discussion in the public debate. Indeed, in the course of the controversy,
the evaluation and management of risks has evolved from a model where
decision making is restricted to a qualified group of experts and policy makers,
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to a model of public negotiation of risks (Aude´tat, November and Kaufmann,
2005). Although the agenda for discussion was initially focused on potential risks
of GM food, the widening controversy contributed to democratize and enrich the
public debate, which eventually included economic, environmental, and health-
related issues of genetically modified crops (Kaufmann et al., 2004).
In 2005, a referendum was held to decide whether or not to prohibit the use of
GM plants for a period of 5 years. The majority of the voters accepted the five-year
moratorium, which was later extended to November 2013. The ostensible purpose
of the moratorium was to provide time for evaluation of potential benefits and risks
of GM plants, as well as their social acceptability. To this end, a national research
program was implemented by the SNSF (NRP 59) (http://www.nrp59.ch/e_index.
cfm). Since the empirical part of this research necessitates field testing of GM
plants, and since such tests raise fierce opposition by legal and illegal means, it is
doubtful whether this research program will provide enough results to inform public
policy on this matter.
Reproductive Medicine
Discussions regarding reproductive medicine in Switzerland have centered on
what should be allowed on the one hand and what should be covered by health
insurance on the other. Broadly speaking and as outlined above (see section
“Beginning of Life”), Swiss legislation on reproductive technologies rests on the
paradigm of application within a nuclear family and recognizes an individual’s
right to know her biological ascendency.
As regards abortion, the Swiss Parliament adopted a reform of criminal law in
2002, basing the protection of embryos and fetuses on a “gradualist” view of their
moral status – the view according to which the appropriate protections grow, as it
were, along with it. As outlined in section “Health and Disease,” contraception and
fertility treatments are generally excluded from health coverage, as both are
considered lifestyle choices rather than health issues.
Medical Research
International principles and guidelines are applied to research with human subjects
in Switzerland. Swiss law makes explicit reference to the ICH guidelines for Good
Clinical Practice, and Swiss Academy of Medical Sciences (SAMS) recommenda-
tions (http://www.samw.ch/de/Ethik/Richtlinien/Archiv.html) refer to the declara-
tion of Helsinki. Specific issues have nevertheless been raised in the Swiss context,
in particular, since the first project for a federal law on research with human
subjects was put to public consultation in 2006. Three issues have been the object
of particular debate.
First, the scope of protections for human subjects of research outside of biomed-
ical sciences is controversial. On the one hand, it is difficult to see how the area of
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researchwhere human subjects incur risks shouldmake a difference to the protection
they are given. On the other hand, ethical codes and oversight bodies are often
younger, fewer, or even nonexistent in fields other than biomedical science. When it
came to defining the required protections’ scope of application, the authors of the
law project rejected application based on the discipline or professional group of the
investigators as too difficult to define exhaustively and too likely to include research
involving no risk to human participants. They also rejected application based on the
degree of risk, based on the lack of bodies competent to review such research outside
the scope of biomedicine. They defined the scope of protection, which includes
ethics committee review, based on two criteria (Duetz and Gruberski, 2009):
1. Research on human disease and the development and functioning of the human
body, where the term “disease” is understood broadly and includes psycholog-
ical health impairments.
2. A risk threshold based on the possibility of harm to human dignity and personal
integrity: This is defined by the exclusion of research on in vitro embryos,
anonymous biological material, and anonymously obtained or completely
anonymized health-related data.
Second, federalism has led to decentralized review of multicenter studies even
within Switzerland, and coordination of ethics review by different ethics commit-
tees has proved difficult. Recently, the working group of Ethics Review Commit-
tees has implemented a rotating centralized review to facilitate multicenter review.
Third, the interface between research with animals and research with human
subjects is a particular point of tension in Switzerland. Research with animals is
particularly strictly regulated in Switzerland, based on a constitutional clause
protecting the integrity of living organisms – or the “dignity of creatures” in the
German version. The “dignity” of animals is explicitly different from human
dignity: it means that animal interests must be considered in the balance of risks
and benefits but can nevertheless be subordinated to greater human interests
(ECNH, 2008). In practice, application predictably remains difficult. In 2008,
a decision to stop two experiments on monkeys was upheld by the Swiss Supreme
Court based on the uncertainty and distance of the expected clinical applications in
view of the burden imposed on nonhuman primates. As such decisions illustrate, the
appropriate thresholds to apply in balancing human and animal interests remain
controversial.
Public Health
Ethical issues in public health tend to cluster around three main issues: tensions
between public health efforts and individual self-determination, questions
regarding legitimacy and appropriate decision makers, and difficulties in
distinguishing public interventions for the prevention of disease on the one
hand and the moralization of health on the other. In Switzerland, a strong focus
on individual self-determination, combined with the cantonal organization of
many aspects of the health care system, has tended to make concerted public
1548 G. Barazzetti et al.
health efforts more difficult. Antismoking campaigns, for example, have tended
to focus on individual efforts rather than on limits to the availability of tobacco.
It is only when it became clear that smoking was harmful to others that bans on
smoking in public spaces were implemented. Information campaigns for organ
transplantation have also been criticized for focusing on neutrality and avoiding
any appearance of promoting organ donation. This focus on individual self-
determination extends to the prevention of infectious diseases, with very few
mandatory vaccinations and some resurgence, for example, of measles as one
consequence. During the beginning of the AIDS pandemic, public health inter-
ventions struck many as signalizing a shift away from the moralization of
sexuality as advertisement for condoms were used in public spaces to promote
effective protection. More recently, however, health itself has tended to risk
becoming moralized as part of prevention campaigns aimed, for example, at the
prevention of smoking or obesity.
Infectious Diseases
As outlined above (see section “What Have Been the Steps/Measures Taken”), the
Swiss law on epidemics dates back to 1974 and has never been amended since. At
the beginning of the AIDS pandemic and during concerns regarding avian flu
outbreaks, no specific standards were introduced, although information campaigns
were strongly supported by public authorities to prevent the spreading of the disease
in the country. As outlined under Public health, however, a strong focus on
individual self-determination, combined with the cantonal organization of many
aspects of the health care system, has tended to make concerted public health efforts
in prevention more difficult. This focus on individual self-determination extends to
the prevention of infectious diseases, with very few mandatory vaccinations and
some resurgence, for example, of measles as one consequence.
Transplantation Medicine and Organ Donation
In 2004, the Confederation adopted a federal law on organ transplantation. Before
that date, this practice was regulated by the directives of the Swiss Academy of
Medical Sciences (SAMS) (Available at http://www.samw.ch/en/Ethics/Guide-
lines/Archive.html) and by 15 different cantonal laws. Notwithstanding the new
federal regulation and the information campaigns for the promotion of organ
donation, the practice is limited by the significant shortage of organs available for
transplantation. There are important differences in the attitude of Swiss citizens
with regard to transplantation. The paucity of cadaveric donations in the country
has contributed to increase the number of transplants from living donors, a practice
strictly regulated by the new federal law. According to the current legislation,
explicit consent to organ donation should be given by persons before death or
should be witnessed by family members after death.
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The Confederation mandated the SAMS to draw recommendations for clinicians
on both the definition of brain death and the procedures to assess it. The SAMS
regularly updates these directives (Updated versions are available at http://www.
samw.ch/en/Ethics/Guidelines/Currently-valid-guidelines.html).
More recently, the Swiss Parliament has discussed the adoption of an implicit
consent to organ donation. The Swiss National Advisory Commission on Biomed-
ical Ethics raised several concerns on the ethical implications of this measure for
medical practice.
New legal provisions have been introduced on allocation of organs available for
transplantation, with a view to establish stringent eligibility criteria for patients on
the basis of urgency and efficacy. At present, the practice of xenotransplantation,
which was extensively discussed as an alternative to organ transplantation, has been
progressively abandoned and eventually prohibited by law due to the high risks of
transmission of zoogenic pathogens.
Emerging Technologies
Discussion of new emerging technologies in Switzerland is mainly, although not
exclusively, focused on nanotechnology. Similarly to what happened in the case of
the GMO controversy, the agenda for discussion is dominated by concerns about
risks and safety of nanoparticles. This approach is manifested in the national
research program founded by the Swiss National Science Foundation (SNSF) to
investigate impacts of biomedical and environmental use of nanomaterials (NRP 64)
(http://www.nfp64.ch/E/Pages/home.aspx), as well as in the initiatives launched by
the Federal Office of Public Health (FOPH) (http://www.bag.admin.ch/index.html?
lang¼en), such as the platform for public dialogue NANO and the Precautionary
Matrix for Synthetic Nanomaterials, a method to assess potential risks of the
production of nanomaterials.
Very recently, some arenas of discussions have been developed, such as
the following: the publifocus organized by the Centre for Technology Assessment
TA-SWISS (http://www.ta-swiss.ch/en/projects/nanotechnologies/); the newsletter
published by the Innovation Society, an independent consulting company based at
the Technology Center of the Federal Institute of Materials Science and Technol-
ogy in St. Gallen (http://www.innovationsgesellschaft.ch/index.php?page¼93);
and Nanopublic (http://www.unil.ch/nanopublic/page32013.html), the nanotech-
nologies and society interdisciplinary platform aiming at fostering dialogue
between the Swiss nanotechnology stakeholders.
Intensive Care
Discussion of ethical issues in intensive care has focused on questions raised at the
end of life and on admission criteria in triage situations. It is generally accepted in
Switzerland that competent patients have a right to refuse medical interventions,
including life-sustaining measures. Consequently, withholding and withdrawing
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therapy is an accepted part of medical practice. It is further accepted that futility, the
absence of hope that an intervention will bring sufficient benefit to the patient to
warrant the burden to that patient, can justifiably ground a decision to withhold or
withdraw medical interventions. One consequence is that, among patients who die
in Swiss intensive care units, a significant number does so following a decision to
limit life-sustaining measures. Such decisions are usually based on consensus
within interdisciplinary teams, on agreement with competent patients, and in the
case of incompetent patients on discussions with family members regarding what
the patient would have wanted. A revision of the Swiss Civil Code, giving greater
representation power to family members of incapacitated patients, should result in
a shift toward greater participation of families in such decisions in the near future.
Issues arising in the allocation of intensive care beds have been minimized by
nationwide coordination among intensive care units. As indications for intensive
care grow, however, such issues have been increasingly debated at the local level.
The Swiss Academy of Medical Sciences (SAMS) published guidelines on
ethical issues in intensive care in 1999 (SAMS, 1999). Separate guidelines for the
treatment of severely premature newborns have been regularly updated by the
Swiss Society for Neonatology.
Palliative Care
As outlined in section “End of Life”, discussions about palliative care and advanced
directives have rapidly reached a general consensus. Palliative care is promoted and
sustained by the Confederation and the cantons. Advanced directives, which
already exist in several cantons, are recognized on a federal level by a revision of
the Swiss civil code, as of 2013.
Care for the Elderly
Although discussions on care for the elderly are similar in Switzerland and other
countries, four issues can be noted. First, the medical specialty of geriatrics or
gerontology is rather new in clinical medicine, and in Switzerland, it has faced
difficulties in identifying its specificities in clinical settings. As clinical approaches
in gerontology tend to be rather different from those in other areas of medicine
treating elderly patients, this has meant that ethical issues in the care of the elderly
have varied with the clinical setting. Second, discussions of ethical issues in old age
have tended to focus on practical clinical issues (Monod, Chiolero, B€ula and
Benaroyo, 2011), such as adapting medical interventions to old age, how to define
the proper aims of medicine in old age, attempting to avoid both critiques of
“agism,” or doing too little, and concerns that medicine is doing too much. Third,
antiaging medicine has been a focus of research, and this has led to considerable
discussions regarding ethical issues raised by medical enhancements. Fourth, as in
many other western countries, issues are raised by the coverage of elder care.
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As resource constraints meet rising needs, concerns have also been voiced that the
elderly could become a population particularly vulnerable to unjustified rationing.
In Switzerland, coverage by medical insurance is based on the presence of disease
and the indication for medical treatment. Dependence for the activities of daily
living is not considered a disease, and thus it is not covered by insurance. Any such
costs are paid out of pocket by individuals, with state help available for those who
become indigent as a result. Although this still affects a minority of the population
aged >85, its unpredictability has led to calls to extend insurance to cover long-
term care. Tensions arising between the costs which this would involve and the
requirements for solidarity in facing old age are an ongoing debate.
Ethical guidelines for the care of dependent elderly patients were published by
the Swiss Academy of Medical Sciences (SAMS) in 2004 (SAMS, 2004b). They
focus on issues including appropriate care, continuity of care, interdisciplinary
collaboration and collaboration with family members, advance directives, informed
consent, decisions for incapacitated patients, adaptation of prevention, acute care,
rehabilitation and palliative care to old age, and end-of-life issues.
Chronic Diseases
Issues related, among others, to access to health care and indications for palliative
care do arise in the context of chronic diseases, they are not different from those
outlined in the sections “Health and Disease, Health Care System, Access to Health
Care, Traditional Medicine” above.
Psychiatric Care
All themain issues raised in other areas ofmedicine are also raised in psychiatric care.
A further focus has centered in Switzerland on whether suicide assistance should be
allowed in the case of competent patients suffering from psychiatric diseases. In 2006,
a Swiss Supreme Court ruling established that suicide assistance could be allowed in
the case of competent psychiatric patients on the strict condition that their wish to die
be well-considered, durable, and free of any outside influence based on an expert
psychiatric evaluation. Controversies on this topic, however, are still ongoing.
Pediatric Care
Various issues outlined in the above sections are also relevant to pediatric care
(Kind, 2009). In the Swiss context, it should be noted that the threshold which
allows a patient to make her own decisions regarding health care is not adulthood
but decision-making capacity regarding the choice at stake. “Mature minors” who
are patients in Switzerland can thus consent to – or refuse – medical interventions,
including life-saving interventions. Specific laws require additional parental
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consent in cases where greater protection is necessary – such as consent for
participation in research – and in some cases, minors are excluded from particularly
risky altruistic medical interventions entirely – such as live donation of solid
organs. Such cases, however, are exceptions. Competent minors’ consent is also
required to divulge any confidential information to their parents or other guardians.
Emergency Care
Aside from a brief attempt in 2007 to exclude illegal immigrants from emergency
care, which was swiftly rejected by the Swiss Supreme Court, the Swiss National
Advisory Commission on Biomedical Ethics (NEK-CNE), and Swiss health care
providers in their practice, no specific ethical issues have been raised in Switzerland
regarding emergency care.
General Practice
All the main issues raised in other areas of medicine are also raised in general
practice. More recently, policy issues regarding general practice, such as the
usefulness of a gatekeeper role within the health care system or the importance of
increasing the attraction of general practice for young physicians, have been
increasingly debated within the health policy discussion. Moreover, Switzerland
is a destination country in the global medical brain drain, which clearly raises
ethical issues far beyond those which have been addressed to date.
Health Promotion and Education
See section “Public Health” above.
Scientific and Professional Integrity, Conflict of Interest, Corruption
Issues of scientific fraud and other breaches of scientific integrity have regularly
surfaced in Swiss academic life, as is the case elsewhere. Beginning in the 1980s,
there was increased controversy and dissatisfaction about the informal manner
with which these cases were traditionally handled by academia. In particular,
the lack of clear procedural rules meant that investigations of alleged
scientific misconduct by academic authorities were easy targets for legal
challenge. This led universities and the Swiss Academies of Arts and Sciences
(http://www.swiss-academies.ch/en/index/Portrait.html) to adopt more detailed,
formal regulations. The Swiss Academy of Medical Sciences (SAMS) released
a set of regulations on scientific integrity in 2002 (SAMS, 2002). This document
defined the nature and scope of scientific misconduct in biomedical research and
perhaps even more importantly, established a detailed procedure to investigate
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accusations of scientific misconduct. The document was in line with similar
guidelines on this topic issued by various national and international bodies (e.g.,
European Science Foundation – US Office of Research Integrity: Research Integ-
rity: global responsibility to foster common standards (http://www.esf.org/index.
php?id¼4479). These guidelines were influential in getting universities to develop
their own framework for issues of scientific integrity, by adapting the rules that
had evolved in the context of medical faculties and biomedical research institutes
to a broader range of scientific and scholarly fields.
In 2007, the Swiss Academies of Arts and Sciences issued a memorandum in
which they define basic principles and offer to help research institutions in setting
up specific rules and procedures. This was followed by setting up a permanent
commission on scientific integrity, which issued a much more detailed document in
2008 delineating ethical principles and procedural rules (Swiss Academies of Arts
and Sciences, 2008). The principles tend to go beyond the “FFP core” (fabrication
or falsification of research results, plagiarism) familiar to Anglo-American
researchers and include attitudinal goals concerning, for instance, the role model
provided by senior researchers, the importance of quality vs. quantity of research
output, and the responsible use of the constitutionally guaranteed freedom to do
research. The procedural rules involve a four-pronged organization of integrity
protection. This includes an ombudsperson who deals with initial complaints and
may arbitrate minor cases and an integrity protection commissioner who selects
a suitable fact-finding panel to conduct the inquiry and, in case solid evidence of
misconduct is found, passes the results to a decision-making panel to whom
authority to decide the case has been delegated by the dean, university president,
or director of the research institution. This somewhat complex system was felt to be
needed in order to guarantee due process and the presumption of innocence as well
as protecting whistleblowers and safeguarding relevant evidence.
Relations with Industry and Donors/Sponsors
The relationship between the pharmaceutical industry on the one hand and
academic biomedical research and medical practitioners on the other has special
significance in Switzerland. Some of the largest pharmaceutical companies in the
world have originated in this country, where they still maintain their headquar-
ters and a significant proportion of research and manufacturing facilities (for how
long is unclear). This means that the pharmaceutical industry enjoys a great deal
of political influence, for instance in negotiating drug prices with Swiss health
authorities. It also entails a strong presence of industry in postgraduate medical
education and academic medicine. As regards medical research, this close con-
nection between academia and industry is not always, or necessarily,
problematic. In fact, during the “golden age” (roughly from the 1950s to the
1980s), when biomedical advances quickly resulted in the availability of whole
classes of important new drugs, this relationship was quite constructive and
useful. In recent decades, however, important global changes have affected
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both sides of this divide. As a result, it has become more and more apparent that
the primary interests of universities, industry, and public health are often at odds
with each other. The old “cozy” relationship came increasingly under fire, and it
was again the Swiss Academy of Medical Sciences (SAMS) which took the lead
in setting up regulations to deal with these issues. Its guidelines on this subject
were initially greeted with skepticism and controversy but are now firmly
established (SAMS, 2005). These include not only general principles but also
specific and practical rules, especially as regards industry-initiated or industry-
supported grand rounds and postgraduate training sessions.
One industrial sector that poses a unique challenge to scientific integrity and
public health is the tobacco industry. Several world companies involved in
cigarette manufacturing have established their headquarters in Switzerland,
where they happen to be beyond the reach of American and European law.
They enjoy a position of enviable privilege and influence, with dismal conse-
quences as regards scientific integrity (University of Geneva, 2004; Diethelm
et al., 2005) and health policy, as evidenced by the fact that Switzerland is one of
the few countries that has not ratified the WHO tobacco convention.
Other: Addiction
Since 1994, Switzerland has had a rather unique policy on illegal addictive drugs,
based on a fourfold objective: prevention, therapy, risk reduction, and repression.
Risk reduction entails the setting up of “injection rooms,” where persons addicted
to opioids can inject themselves in safe conditions and, more controversially, the
provision of heroin under medical supervision to prescreened, highly dependent
drug users (foundation Sucht Info Schweiz: http://www.suchtschweiz.ch/de/
themen/). From its onset, this program was considered experimental and involved
continuous evaluation of its efficacy in improving the health and social integration
of long-term drug users. This attracted a great deal of attention and often skepticism
on the domestic and international scene. In a sense, this reaction is understandable
since the pragmatic and evidence-based Swiss approach is inherently alien to the
“moral crusade” which often energizes the “war on drugs” on a global scale.
This risk reduction policy was confirmed by a majority of Swiss voters in
a referendum held in 2008. Recently, the Swiss experiment has been viewed
more sympathetically from abroad, as the failure of a purely prohibitionist stance
is increasingly and more openly discussed internationally.
Future Challenges
The ongoing debate on eligibility criteria for patients to be listed for organ trans-
plantation and the paucity of organs available in the country show that cultural forces
and individual preferences have important impacts on the implementation of health
care policies and need to be carefully examined. This debate shows that the authority
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of the state to deal with health policy issues through nudge campaigns aiming to
affect individual choices should be reconsidered. However, it also raises the ques-
tion of whether the state can endorse some ethical perspective or should be neutral on
bioethical issues. Further discussion is needed to develop a richer understanding of
the societal implications of individual choices and of the role of the state in this field.
Although the Swiss health care system guarantees a universal coverage based on
individual health insurance, the increasing rate of out-of-pocket payments has
raised ethical concerns regarding barriers to access to needed care. The concept
of personal responsibility that fuels the ethos of health care coverage needs to be
reconsidered to prevent the state-regulated but privately managed health insurance
system from producing health care inequalities in the country.
A significant proportion of academic biomedical research in Switzerland is
funded by pharmaceutical companies, and even modest changes in the pharmaceu-
tical industry may have important consequences on medical research and practice.
Therefore, future challenges also include the discussion of ethical issues in the
governance of biomedical research in the country.
Since Switzerland has developed an outstanding environment for technological
innovation and industrial development in the life sciences, it is likely that issues
related to science policy, both on the national level and internationally, will become
more urgent in the near future.
Summary Conclusions
The Swiss debate over controversial bioethical issues in the country is characterized
by the coexistence of academic expertise on the one hand and of public participa-
tion in the discussion of possible solutions on the other. Occasionally, public
engagement has influenced the roadmap for regulation, as was the case for genet-
ically modified plants.
Over the last decade, scholars in the field of bioethics have progressively
abandoned the role of exclusive experts in the field and have turned into participants
into a wider debate involving multiple competences and varied public actors. Most
importantly, however, direct democracy, decentralized governance, and the value
placed on individual choices have largely influenced debates, laws, and practices
regarding many bioethical issues.
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